Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)

기사 요약

Johnson & Johnson beats Q3 2026 earnings expectations with $25.39B in sales and raises its full-year revenue and profit guidance.